Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging

JAMA Neurology

Volumn 70, Issue 7, 2013, Pages 883-890

  Friedman, Seth D ^a   Baker, Laura D ^b,c,e   Borson, Soo ^b,d   Jensen, J Eric ^a   Barsness, Suzanne M ^a   Craft, Suzanne ^a,c,e   Merriam, George R ^b,c   Otto, Randolph K ^a   Novotny, Edward J ^a   Vitiello, Michael V ^b  

^a SEATTLE CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d HARVARD UNIVERSITY   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; CREATINE; CREATINE PHOSPHATE; GLUCOSE; GLUTAMIC ACID; GROWTH HORMONE RELEASING FACTOR; INOSITOL; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; PLACEBO; SOMATOMEDIN C; TESAMORELIN;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ADULT; AGED; ALZHEIMER DISEASE; ARTHRALGIA; ARTICLE; BEDTIME DOSAGE; BLOOD SAMPLING; BRAIN RADIOGRAPHY; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; EXECUTIVE FUNCTION; FEMALE; FLUID RETENTION; FRONTAL CORTEX; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROTRANSMITTER RELEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VERBAL MEMORY;

EID: 84880316474     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.1425     Document Type: Article

References (50)

1. Lieberman SA, Hoffman AR. The somatopause: should growth hormone deficiency in older people be treated? Clin Geriatr Med. 1997;13(4):671-684.
2. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14(1):20-39.
3. Donahue CP, Kosik KS, Shors TJ. Growth hormone is produced within the hippocampus where it responds to age, sex, and stress. Proc Natl Acad Sci U S A. 2006;103(15):6031-6036.
4. Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48.
5. Merriam GR, Buchner DM, Prinz PN, Schwartz RS, Vitiello MV. Potential applications of GH secretagogs in the evaluation and treatment of the age-related decline in growth hormone secretion. Endocrine. 1997;7(1):49-52.
6. Lichtenwalner RJ, ForbesME, Bennett SA, Lynch CD, Sonntag WE, Riddle DR. Intracerebroventricular infusion of insulin-like growth factor-I ameliorates the age-related decline in hippocampal neurogenesis. Neuroscience. 2001;107(4):603-613.
7. Markowska AL, MooneyM, Sonntag WE. Insulin-like growth factor-1 ameliorates age-related behavioral deficits. Neuroscience. 1998;87(3): 559-569.
8. Ramsey MM, Weiner JL, Moore TP, Carter CS, Sonntag WE. Growth hormone treatment attenuates age-related changes in hippocampal short-term plasticity and spatial learning. Neuroscience. 2004;129(1):119-127.
9. Thornton PL, IngramRL, Sonntag WE. Chronic [D-Ala2]-growth hormone-releasing hormone administration attenuates age-related deficits in spatial memory. J Gerontol A Biol Sci Med Sci. 2000;55(2):B106-B112.
10. Baum HB, Katznelson L, Sherman JC, et al. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab. 1998;83(9):3184-3189.
11. Deijen JB, de Boer H, Blok GJ, van der Veen EA. Cognitive impairments and mood disturbances in growth hormone deficient men. Psychoneuroendocrinology. 1996;21(3):313-322.
12. PapadakisMA, Grady D, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med. 1996;124(8):708-716.
13. Soares CN, Musolino NR, Cunha Neto M, et al. Impact of recombinant human growth hormone (RH-GH) treatment on psychiatric, neuropsychological and clinical profiles of GH deficient adults: a placebo-controlled trial. Arq Neuropsiquiatr. 1999;57(2A):182-189.
14. Friedlander AL, Butterfield GE, Moynihan S, et al. One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. J Clin Endocrinol Metab. 2001;86(4):1496-1503.
15. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11): 1420-1429.
16. Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006;27(2): 318-323.
17. Deak F, Sonntag WE. Aging, synaptic dysfunction, and insulin-like growth factor (IGF)-1. J Gerontol A Biol Sci Med Sci. 2012;67(6):611-625.
18. Arwert LI, Veltman DJ, Deijen JB, Lammertsma AA, Jonker C, Drent ML. Memory performance and the growth hormone/insulin-like growth factor axis in elderly: a positron emission tomography study. Neuroendocrinology. 2005;81(1):31-40.
19. van DamPS, de Winter CF, de Vries R, et al. Childhood-onset growth hormone deficiency, cognitive function and brain N-acetylaspartate. Psychoneuroendocrinology. 2005;30(4):357-363.
20. Jensen JE, Licata SC, Ongür D, et al. Quantification of J-resolved proton spectra in two-dimensions with LCModel using GAMMA-simulated basis sets at 4 Tesla. NMR Biomed. 2009;22(7):762-769.
21. Edden RA, Muthukumaraswamy SD, Freeman TC, Singh KD. Orientation discrimination performance is predicted by GABA concentration and gamma oscillation frequency in human primary visual cortex. J Neurosci. 2009;29(50):15721-15726.
22. Novotny EJ Jr, Hyder F, Shevell M, Rothman DL. GABA changes with vigabatrin in the developing human brain. Epilepsia. 1999;40(4):462-466.
23. BartosM, Vida I, Jonas P. Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat Rev Neurosci. 2007;8(1): 45-56.
24. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011;68(1):51-57.
25. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion ofmild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30(8):1104-1113.
26. Ishiwata A, Sakayori O, Minoshima S, Mizumura S, Kitamura S, Katayama Y. Preclinical evidence of Alzheimer changes in progressive mild cognitive impairment: a qualitative and quantitative SPECT study. Acta Neurol Scand. 2006;114(2):91-96.
27. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42(1):85-94.
28. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3): 183-194.
29. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1): 150-158.
30. Edden RA, Pomper MG, Barker PB. In vivo differentiation of N-acetyl aspartyl glutamate from N-acetyl aspartate at 3 Tesla. Magn Reson Med. 2007;57(6):977-982.
31. Cohen J, Cohen P. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Assoc; 1983.
32. Stata. Stata Statistical Software: Release 11 [computer program]. College Station, TX: StataCorp; 2009.
33. Huang W, Alexander GE, Chang L, et al. Brain metabolite concentration and dementia severity in Alzheimer's disease: a 1H MRS study. Neurology. 2001;57(4):626-632.
34. Kantarci K, Jack CR Jr, Xu YC, et al. Regional metabolic patterns inmild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology. 2000;55(2):210-217.
35. Kantarci K, Lowe V, Przybelski SA, et al. Magnetic resonance spectroscopy, ?-amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology. 2011;77(10):951-958.
36. Rossignol E. Genetics and function of neocortical GABAergic interneurons in neurodevelopmental disorders. Neural Plast. 2012;2011:649325. doi:10. 1155/2011/649325.
37. Neale JH, Olszewski RT, Zuo D, et al. Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J Neurochem. 2011;118(4):490-498.
38. Passani LA, Vonsattel JP, Carter RE, Coyle JT. N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Mol Chem Neuropathol. 1997;31(2):97-118.
39. Lodder-Gadaczek J, Becker I, Gieselmann V, Wang-Eckhardt L, Eckhardt M. N-acetylaspartylglutamate synthetase II synthesizes N- acetylaspartylglutamylglutamate. J Biol Chem. 2011;286(19):16693-16706.
40. Ling LL, Hughes LF, Caspary DM. Age-related loss of the GABA synthetic enzyme glutamic acid decarboxylase in rat primary auditory cortex. Neuroscience. 2005;132(4):1103-1113.
41. Majdi M, Ribeiro-da-Silva A, Cuello AC. Variations in excitatory and inhibitory postsynaptic protein content in rat cerebral cortex with respect to aging and cognitive status. Neuroscience. 2009;159(2):896-907.
42. Tanaka DH, Toriumi K, Kubo K, Nabeshima T, Nakajima K. GABAergic precursor transplantation into the prefrontal cortex prevents phencyclidine-induced cognitive deficits. J Neurosci. 2011;31(40):14116-14125.
43. Fujiwara H, ZhengM, Miyamoto A, Hoshino O. Insufficient augmentation of ambient GABA responsible for age-related cognitive deficit. Cogn Process. 2011;12(2):151-159.
44. Boy F, Evans CJ, Edden RA, et al. Dorsolateral prefrontal ?-aminobutyric acid in men predicts individual differences in rash impulsivity. Biol Psychiatry. 2011;70(9):866-872.
45. Goto N, Yoshimura R, Kakeda S, et al. Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia. Hum Psychopharmacol. 2009;24(8):639-645.
46. HenryME, Lauriat TL, Shanahan M, Renshaw PF, Jensen JE. Accuracy and stability of measuring GABA, glutamate, and glutamine by proton magnetic resonance spectroscopy: a phantom study at 4 Tesla. J Magn Reson. 2011;208(2): 210-218.
47. Muthukumaraswamy SD, Edden RA, Jones DK, Swettenham JB, Singh KD. Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humans. Proc Natl Acad Sci U S A. 2009;106(20): 8356-8361.
48. Boy F, Evans CJ, Edden RA, Singh KD, Husain M, Sumner P. Individual differences in subconscious motor control predicted by GABA concentration in SMA. Curr Biol. 2010;20(19):1779-1785.
49. Puts NA, Edden RA, Evans CJ, McGlone F, McGonigle DJ. Regionally specific human GABA concentration correlates with tactile discrimination thresholds. J Neurosci. 2011;31(46):16556-16560.
50. Sumner P, Edden RA, Bompas A, Evans CJ, Singh KD. More GABA, less distraction: a neurochemical predictor of motor decision speed. Nat Neurosci. 2010;13(7):825-827.